Table 2.
Univariate and multivariate analyses of various factors for progression-free survival
| Variable | No. | Univariate analysis |
Multivariate analysis |
||
|---|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | ||
| Age (yr) | 88 | 1.013 (0.986-1.040) | 0.360 | ||
| FIGO stage | |||||
| 1-2 | 15 | 1 (reference) | 1 (reference) | ||
| 3-4 | 73 | 3.226 (1.034-10.469) | 0.044 | 5.071 (1.170-12.608) | 0.027 |
| LN metastasis | |||||
| Yes | 41 | 1 (reference) | - | ||
| No | 43 | 1.712 (0.924-3.170) | 0.087 | - | - |
| Lymphovascular invasion | |||||
| Yes | 40 | 1 (reference) | - | ||
| No | 48 | 1.619 (0.876-2.994) | 0.124 | - | - |
| High-grade tumor | |||||
| Yes | 22 | 1 (reference) | 1 (reference) | ||
| No | 66 | 0.273 (0.108-0.719) | 0.008 | 0.458 (0.231-0.909) | 0.026 |
| Residual disease | |||||
| NGR | 50 | 1 (reference) | 1 (reference) | ||
| < 1 cm | 26 | 2.113 (1.075-4.155) | 0.030 | 1.936 (0.965-3.882) | 0.063 |
| ≥ 1 cm | 12 | 1.869 (0.778-4.491) | 0.162 | 1.485 (0.585-3.771) | 0.405 |
| Tumorigenicity | |||||
| No | 41 | 1 (reference) | 1 (reference) | ||
| Yes | 47 | 1.949 (1.353-3.140) | 0.043 | 2.196 (1.123-4.292) | 0.021 |
HR, hazard ratio; CI, confidential interval; FIGO, The International Federation of Gynecology and Obstetrics; LN, lymph node; NGR, no gross residual disease.